Aligos completes enrollment in Phase 2 B-SUPREME trial for chronic hepatitis B drug pevifoscorvir sodiumPUBT·Jul 13 at 07:05 AMALGS-0.21%
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga_article·Jul 6 at 04:05 PMRXST+0.64%LUCY-3.89%
Aligos Therapeutics receives USD 25 million upfront in Greater China pevifoscorvir license deal with AmoytopPUBT·Jul 6 at 03:05 PMALGS-0.21%688278-3.78%
Aligos Therapeutics shareholders approve ESPP share reserve increase, remove evergreen provisionPUBT·Jun 26 at 03:03 PMALGS-0.21%
Lawrence M. Blatt Discloses Investment at Aligos Therapeutics with 5.6% StakeTradingView·Jun 24 at 03:36 PMALGS-0.21%
Here's Why We're A Bit Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn SituationSimplywall·Jun 6 at 08:18 AMALGS-0.21%
Aligos Presents Promising Data For Pevifoscovir Sodium In Treating Hepatitis Bnasdaq·May 27 at 07:55 AMALGS-0.21%FBT+0.76%
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 | ALGS Stock NewsStockTitan·May 26 at 05:31 PMALGS-0.21%BIB+1.72%
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 | ALGS Stock NewsStockTitan·May 12 at 05:05 PMALGS-0.21%LABU+2.48%
